This document discusses the need for new vaccine technologies due to continually emerging pathogens and issues with current production methods. It provides examples of past disease outbreaks and mortality rates. Currently, vaccines are produced using live attenuated viruses, killed viruses, or recombinant subunits. However, these methods have limitations like cold storage requirements, high production costs, complex dosing, and inability to induce long-term immune memory. The document proposes that new technologies like a subunit vaccine produced using lambda bacteriophage could help address these issues.

2. Quick production of a Subunit Vaccine using Lambda Bateriophage

3. • The eradication of Smallpox in 1979.
• Continual emergence of disease outbreaks: Rapidly evolving pathogens
SARS, HIV, West Nile, Mad Cow,
Year Serotype Name Mortality
1918 H1N1 Spanish Flu 21-50million
1957 H2N2 Milder 1-4million
1968 H3N2 Hong Kong Flu 1-4million
1997 H5N1 Asian Flu (avian) 257 with a 60% mortality
2003 SARS ~800
2009 H1N1 Swine flu

4. • Vaccines are currently made using a variety of ‘scaffolds’.
– The infectious agent itself:
• Attenuated or killed virus/bacteria
– ie: MMR vaccine for measles, mumps, rubella
• Or recombinant/subunit vaccines:
– ie. Hepatitis B using the capsid protein, Hepatitis B surface antigen (HBsAg)
• These are all great but new technologies could alleviate current problems.
Including:
–Chain of cold storage
–Cost of production – cell culture, zoonosis risk
–Difficult and complex inoculation regimes
–Immune memory
–Evasive/mutagenic infectious agents – HIV

7. A
A B
C D

8. AB
B
CC

9. A B C

11. Open source platform

12. The Rancourt Lab - Derrick Rancourt and all members past and present
My committee – Frank Jirik, Steve Robbins, Mike Surrette
Oliver Bathe
Southern Alberta Cancer Research Group
William H. Davies Medical
Research Scholarship